RESUMO
OBJECTIVE:To investigate the clinical efficacy and safety of butylphthalide combined with nimodipine in the treat-ment of vascular cognitive impairment. METHODS:Totally 156 patients with vascular cognitive impairment were randomly divided into control group and observation group. All patients were given anti-platelet,control of blood pressure,lowering blood glucose, lowering statin therapy for stable plaque and symptomatic treatment. On this basis,control group was orally treated with nimodipi-he 30 mg,tid;observation group was orally treated with Butylphthalide capsule 0.2 g based on the treatment of control group,tid. The course lasted for 3 months. The clinic data was observed,including clinical efficacy,and Montreal cognitive assessment(Mo-CA)score,activities of daily living scale(ADL)score,stenosis great vessels distal blood flow velocity and incidence of adverse reactions before and after treatment. RESULTS:The total effective rate in observation group was significantly higher than control group,with significant difference(P<0.05). After treatment,the MoCA score,ADL score and stenosis great vessels distal blood flow velocity in 2 groups were significantly higher than before,and observation group was higher than control group,with signifi-cant differences(P<0.05). There were no obvious adverse reactions during treatment. CONCLUSIONS:Based on the conventional treatment,butylphthalide combined with nimodipine has better efficacy than nimodipine alone in the treatment of vascular cognitive impairment,and can improve the stenosis great vessels distal blood flow velocity better,with similar safety.
